Q. Anti-mitochondrial antibody (AMA) is most commonly seen in:

Explanation

## Correct Answer: B. Primary biliary cholangitis Anti-mitochondrial antibodies (AMA), particularly the M2 subtype (against pyruvate dehydrogenase complex), are the pathognomonic serological marker of **primary biliary cholangitis (PBC)**. AMA is present in 90–95% of PBC patients and is so specific that a positive AMA in the setting of cholestasis essentially confirms the diagnosis without need for liver biopsy in many cases. The antibodies target the inner mitochondrial membrane and drive progressive destruction of intrahepatic bile ducts, leading to cholestasis and eventual cirrhosis. In Indian practice, PBC is less common than in Western populations but remains an important diagnosis in women presenting with pruritus, fatigue, and biochemical cholestasis. The presence of AMA distinguishes PBC from other autoimmune liver diseases and is a key criterion in diagnostic algorithms (AASLD/EASL guidelines). Ursodeoxycholic acid (UDCA) is the standard of care in India, with newer agents like obeticholic acid reserved for AMA-positive patients with inadequate response. ## Why the other options are wrong **A. Systemic lupus erythematosus** — SLE is associated with anti-dsDNA, anti-Smith, and anti-histone antibodies, not AMA. While SLE can cause lupus hepatitis, AMA is not a characteristic antibody in SLE. This is a trap for students who confuse autoimmune liver disease with systemic autoimmune disease. **C. Autoimmune hepatitis** — Autoimmune hepatitis (AIH) is characterized by anti-smooth muscle antibody (ASMA) and anti-nuclear antibody (ANA), not AMA. Although both PBC and AIH are autoimmune liver diseases, they have distinct serological profiles. AMA negativity is actually a criterion that helps exclude PBC in AIH. **D. Primary sclerosing cholangitis** — PSC is typically AMA-negative and instead associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in 50–80% of cases. PSC is often linked to inflammatory bowel disease in Indian populations. The absence of AMA helps differentiate PSC from PBC despite both causing cholestasis. ## High-Yield Facts - **AMA-M2** (anti-pyruvate dehydrogenase) is present in 90–95% of PBC cases and is pathognomonic for the disease. - **PBC diagnostic criteria**: AMA positivity + cholestasis (elevated ALP/GGT) + compatible liver histology (bile duct destruction) = definite PBC. - **AMA-negative PBC** (~5–10% of cases) exists but is rare; these patients have anti-centromere antibodies or anti-gp210 instead. - **UDCA 13–15 mg/kg/day** is the standard first-line therapy in India for AMA-positive PBC; improves transplant-free survival. - **PBC vs PSC distinction**: PBC = AMA+, female predominance, intrahepatic cholestasis; PSC = AMA−, p-ANCA+, extrahepatic involvement, IBD association. ## Mnemonics **AMA = PBC (Not PSC)** **A**nti-**M**itochondrial **A**ntibody = **P**rimary **B**iliary **C**holangitis. Remember: AMA is the 'signature' of PBC; PSC has p-ANCA instead. Use this when you see 'AMA' in the stem — think PBC first. **Autoimmune Liver Disease Serology** **PBC** = AMA (M2); **AIH** = ASMA/ANA; **PSC** = p-ANCA. This 1:1 pairing helps you eliminate wrong options quickly in any autoimmune liver disease question. ## NBE Trap NBE pairs "autoimmune liver disease" with "antibody" to lure students into confusing PBC's AMA with AIH's ASMA or PSC's p-ANCA. The trap is assuming all autoimmune liver diseases share the same antibody profile. ## Clinical Pearl In Indian women presenting with pruritus and fatigue, a positive AMA should immediately raise suspicion for PBC even if liver enzymes are only mildly elevated. Early diagnosis and UDCA initiation can slow progression and prevent cirrhosis-related complications like variceal bleeding and hepatic encephalopathy. _Reference: Robbins Ch. 18 (Liver); Harrison Ch. 328 (Cholestasis); KD Tripathi Ch. 14 (Immunology of Liver Disease)_